Abstract:Background HS016, a biosimilar to China-licensed adalimumab, has an identical amino acid sequence, similar physicochemical and in vitro functional properties to China-licensed adalimumab. Objectives The primary objective of this study was to demonstrate PK equivalence between HS016 and China-licensed adalimumab. PK characteristics, safety, tolerability and immunogenicity were investigated as secondary objectives. Methods The first-in-human study was a randomized, double-blind, parallel-control, single-dose study conducted in 136 healthy male subjects at 1 site in China. Subjects were randomized to receive a 40 mg subcutaneous injection of either HS016 or China-licensed adalimumab and were followed up for 70 days. Blood samples were taken pre-dose and at multiple intervals to day 70. The primary outcomes were area under the concentration-time curve from time zero to time t (AUC0-t) area under the concentration-time curve from time zero to infinity (AUC0-∞), and maximum concentration (Cmax). The secondary endpoints were the time taken to reach the maximum concentration(*Tmax), elimination half-life (T1/2) etc. Equivalence for the primary outcomes were to be concluded if the 90% confidence intervals (CIs) for the ratio of geometric least squares means (LS Means) of the groups compared were completely contained within the pre-defined equivalence margin of 0.8 to 1.25 using analysis of variance (ANOVA). Safety indicators mainly included physical examination, vital signs, laboratory examination, electrocardiogram, chest X-ray, etc. Immunogenicity evaluation explored kinetics and magnitude of anti-drug antibody (ADA) and its neutralizing ability of Neutralizing ADA. Results The 90% confidence intervals of geometric least squares means ratios (GMR) of Cmax, AUC0-∞and AUC0-t between HS016 and China-licensed adalimumab arms were (0.9855,1.1359),(0.8743,1.0841) and (0.8724, 1.0605). The 90% confidence intervals of all GMRs fell within pre-specified confidence bounds of 80% to 125%. Of the 136 subjects, 128 had adverse events (AEs) with 63 (92.6%) and 65 (95.6%) AEs occurring in the HS016 and China-licensed adalimumab, respectively. Among these AEs, 172 from 50 subjects (73.5%) in HS016 group and 148 from 55 subject (80.9%) in China-licensed adalimumab were treatment emergent adverse event. The proportion of confirmed anti-drug antibody responses in the 2 study arms were, 25.0% (17 cases) and 22.1% (15 cases) at day 14, 50.0% (34 cases) and 42.6% (29 cases) at day 42, for the HS016 and China-licensed adalimumab arms, respectively. Neutralizing antibodies were all negative at day 14 for both groups, except 2 cases (3.7%) and 1 case (1.6%) at day 42, for the HS016 and China-licensed adalimumab arms, respectively. Conclusion It is concluded that HS016 have shown a similar PK to china -licensed adalimumab in healthy male subjects, and no meaningful differences in safety of immunogenicity were observed. Disclosure of Interests None declared

Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria

Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers

Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial

The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects

Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data

Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of Evolocumab in Healthy Chinese Subjects

Efficacy and Safety of Risankizumab for Crohn's Disease in Patients from Asian Countries: a Post Hoc Subanalysis of the Global Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

Comparability of Elezanumab Safety, Tolerability, and Pharmacokinetics in Healthy Japanese, Chinese, and White Participants

The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study

Tolerability, safety, and pharmacokinetics of a single intravenous administration of a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody in healthy Chinese volunteers

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects

A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects

A Randomized Controlled Dose-Escalation Study of SSS07, a Humanized Rabbit Anti-Human TNF Alpha Antibody, in Healthy Chinese Adults.

FRI0422 HS016, A PROPOSED ADALIMUMAB BIOSIMILAR, SHOWED EQUIVALENT PHARMACOKINETICS AND SIMILAR SAFETY, IMMUNOGENICITY AND TOLERABILITY TO CHINA-LICENSED ADALIMUMAB IN HEALTHY MALE SUBJECTS, ACCORDING TO A 2.3-MONTHS PHASE I STUDY